Published: Jan 19, 2026
Written by Klarity Editorial Team
Published: Jan 19, 2026

Binge eating disorder (BED) affects millions of Americans, yet many struggle to access appropriate treatment due to geographical limitations, specialist shortages, or scheduling difficulties. Telehealth has emerged as a powerful solution, connecting patients with qualified providers regardless of location. But with varying state regulations and frequent policy changes, many are left wondering: ‘Can I legally receive BED medications through telehealth?’
The good news is that non-controlled medications commonly used for BED treatment—including Topamax (topiramate) and Wellbutrin (bupropion)—can be legally prescribed via telehealth across all 50 states. However, the specific requirements and processes vary by state and provider type. This comprehensive guide cuts through the confusion, providing up-to-date information on telehealth prescribing rules for BED medications as of 2025-2026.
Binge eating disorder is characterized by recurrent episodes of eating abnormally large amounts of food while feeling a lack of control. According to DSM-5 criteria, BED involves eating an extreme amount within a 2-hour period, feeling out of control, and experiencing this at least once weekly for three months, without compensatory behaviors like purging.
While psychotherapy remains a first-line treatment for BED, medications play an important role for many patients:
This guide focuses primarily on topiramate and bupropion, as these non-controlled medications have fewer regulatory barriers for telehealth prescribing.
Before diving into state-specific regulations, it’s important to understand the federal framework:
Non-controlled medications (like Topamax and Wellbutrin) have no federal in-person requirement for telehealth prescribing. These medications were never subject to the Ryan Haight Act restrictions.
Controlled substances (like Vyvanse) are governed by the DEA and subject to stricter rules. As of January 2026, the COVID-19 telehealth prescribing flexibilities for controlled substances remain in effect through December 31, 2026, under the fourth extension.
The key takeaway: From a federal perspective, there are no barriers to prescribing non-controlled medications like topiramate or bupropion via telehealth, as long as the provider follows standard of care requirements.
While federal law sets the baseline, state rules add another layer. Here’s what you need to know about some key states:
The following states have no in-person examination requirement for telehealth prescribing of non-controlled medications:
California: Allows telehealth prescribing with no in-person requirement as long as standard of care is met. A 2025 update (AB 1503) explicitly recognized that asynchronous telehealth counts as a ‘good faith examination.’
Delaware: Permits fully remote prescribing under their Telehealth Act with no examination requirement for non-controlled medications.
Florida: No in-person visit required for non-controlled prescriptions. State restrictions apply only to most Schedule II medications.
Michigan: No specific in-person requirement; telehealth is allowed if standard of care is met.
New York: No state in-person rule for legend drugs. (Note: New York did implement a 2025 regulation requiring in-person exams for controlled substances, but this doesn’t affect Topamax or Wellbutrin.)
Texas: No in-person exam required for non-controlled medications. Texas laws primarily restrict teleprescribing for certain Schedule II medications like those for chronic pain.
Wisconsin: No in-person exam needed; telehealth is permitted if standard of care is maintained.
South Carolina: No explicit in-person requirement; must provide an ‘appropriate evaluation,’ which can be conducted via telemedicine.
Some states require occasional in-person visits for ongoing telehealth treatment:
Alabama: If a patient has more than 4 telehealth visits in 12 months for the same condition, they must see a provider in-person within 1 year. This requirement can be satisfied by a collaborating provider on-site.
Georgia: Must attempt an in-person exam at least annually for ongoing telemedicine care. Initial evaluation via telehealth is allowed if equivalent to an in-person exam.
New Hampshire: Removed prior in-person requirement; telehealth is allowed even for Schedule II-IV medications, but a subsequent in-person exam by a prescriber is required at least every 12 months.
The authority of nurse practitioners (NPs) to prescribe medications varies by state:
In about 34 states plus DC, NPs now have full practice authority (independent prescribing). These include:
In these states, an NP can evaluate and prescribe BED medications without physician oversight.
In the remaining states, NPs must work under a collaborative agreement with a physician:
This typically doesn’t affect patient care directly—it’s a behind-the-scenes regulatory requirement—but you might see both the NP and physician names on your prescription.
Many states require providers to check the state PMP database before prescribing controlled substances. For non-controlled medications like Topamax and Wellbutrin, most states do not mandate PMP checks, though providers may still review medication history as a precaution.
To receive BED medication via telehealth, patients must:
Providers will document that patients meet DSM-5 BED criteria, that informed consent was obtained, and that an appropriate evaluation was performed.
Telehealth providers screen for conditions that might disqualify patients from online treatment, including:
Find the right provider for your needs — select your state to find expert care near you.